Leading BioSciences, Inc. develops therapies to improve human health through therapeutic protection of the gastrointestinal mucosal barrier. The company is headquartered in Carlsbad, California.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-26.49M |
| Operating Margin | 0.00% |
| Return on Equity | -36.40% |
| Return on Assets | -23.40% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.76 |
| Price-to-Book | 2.87 |
| Price-to-Sales (TTM) | 11.78 |
| EV/Revenue | 234.89 |
| EV/EBITDA | 0.57 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $173.58M |
| Float | $133.45M |
| % Insiders | 1.64% |
| % Institutions | 93.95% |
Volatility is currently expanding
ASCENTRA-UC expected to enroll up to 204 patients with moderately to severely active ulcerative colitis across North America and Europe
Board strengthened with extensive biotechnology leadership, strategic transactions and capital markets expertise Company continues to build on PALI-2108 clinical progress as it advances toward Phase 2 development and additional key milestones Denver, CO, June 11, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced the addition of Robert Baltera and Jordan Zwick to its Board of Directors. “We are pleased to welcome both Robert and Jordan to the Palisade Bio Board of Directors,” said JD Finley, Chief Executive Officer of Palisade Bio.
Presentation to highlight fibrostenotic Crohn's disease biology and the potential of a locally bioactivated PDE4 inhibitor prodrug approach
Management presentation to take place on Thursday, June 4 th at 3:45 PM ET Register for the webcast here Denver, CO, May 27, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that JD Finley, Chief Executive Officer, and Dr. Mitchell Jones, President & Chief Medical Officer, will present at the Jefferies Global Healthcare Conference, being held June 2-4, 2026, in New York, New York. The Company's presentation is scheduled for Thursday, June 4, 2026, at 3:45 PM ET.
Advancing potentially best-in-class once-daily oral, locally-activated PDE4 inhibitor prodrug for treatment of IBD Phase 2 Ulcerative Colitis (UC) trial expected to commence 3Q 2026 Strong balance sheet expected to support execution through key clinical readouts Denver, CO, May 12, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today reported financial results for the first quarter ended March 31, 2026 and highlighted continued clinical advancements of its lead program, PALI-2108, including recent data readouts and anticipated Phase 2 trial initiations. Building on positive Phase 1a and Phase 1b ulcerative colitis cohort data previously reported, the Company recently reported results from the Phase 1b fibrostenotic Crohn's disease (“FSCD”) cohort, extending the clinical support for the continued development of PALI-2108 across multiple inflammatory bowel disease (“IBD”) indications.
Data demonstrate colon tissue PDE4/cAMP pathway modulation and sustained active metabolite exposure above IC90 across the dosing interval
Poster presentation scheduled for Tuesday, May 5th at 12:30 PM CDT Denver, CO, April 16, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that data from its lead program, PALI-2108, has been selected for poster presentation at Digestive Disease Week ® (DDW) 2026, taking place May 2–5, 2026 in Chicago. The Company will be in attendance alongside members of its Clinical Advisory Board (CAB), further reinforcing its engagement with leading experts in inflammatory bowel disease as it advances PALI-2108 toward the clinic.
Virtual presentation scheduled for Thursday, April 16th at 2:15 PM ET Access the webcast here Denver, CO, April 08, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that JD Finley, Chief Executive Officer, and Dr. Mitchell Jones, President & Chief Medical Officer, will present at the Needham & Co. 25th Annual Healthcare Conference, being held in a virtual format April 14–17, 2026. The Company's virtual presentation is scheduled for Thursday, April 16, 2026, from 2:15 PM to 2:55 PM ET in Track 3.
